DE964859T1 - Neues verfahren - Google Patents

Neues verfahren

Info

Publication number
DE964859T1
DE964859T1 DE0964859T DE98953132T DE964859T1 DE 964859 T1 DE964859 T1 DE 964859T1 DE 0964859 T DE0964859 T DE 0964859T DE 98953132 T DE98953132 T DE 98953132T DE 964859 T1 DE964859 T1 DE 964859T1
Authority
DE
Germany
Prior art keywords
process according
omeprazole
prepared
methoxy
titanium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE0964859T
Other languages
English (en)
Inventor
Hanna Cotton
Magnus Larsson
Anders Mattson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra AB filed Critical Astra AB
Publication of DE964859T1 publication Critical patent/DE964859T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)

Claims (13)

Patentansprüche
1. Verfahren zur Herstellung von Omeprazol, bei dem man 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl]thio]-lH-benzimidazol in einem organischen Lösungsmittel mit einem Oxidationsmittel und gegebenenfalls in Gegenwart einer Base oxidiert, dadurch gekennzeichnet, daß man die Oxidation in Gegenwart eines Titankomplexes durchführt.
2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß man die Oxidation in Gegenwart einer Base durchführt.
3. Verfahren nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß man den Titankomplex aus einer Titan(IV)-Verbindung und einem Enantiomerengemisch chiraler Liganden herstellt.
4. Verfahren nach Anspruch 3, dadurch gekennzeichnet, daß man als Enantiomerengemisch ein racemisches Gemisch einsetzt.
5. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß man den Titankomplex aus einer Titan(IV)-Verbindung und einem achiralen Liganden herstellt.
6. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß man aus der Reaktionsmischung Omeprazol ausfällt.
7. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß man keinen Extraktionsschritt durchführt.
8. Verfahren nach einem der Ansprüche 1-7, dadurch gekennzeichnet, daß man den Titankomplex in Gegenwart von 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]thio]-lH-benzimidazol herstellt.
9. Verfahren nach einem der Ansprüche 1-8, dadurch gekennzeichnet, daß man als Oxidationsmittel Cumolhydroperoxid oder tert.-Butylhydroperoxid einsetzt.
10. Verfahren nach einem der Ansprüche 1-9, dadurch gekennzeichnet, daß man als organisches Lösungsmittel
Toluol einsetzt.
11. Verfahren nach einem der Ansprüche 1-10, dadurch gekennzeichnet, daß man als Base Triethylamin oder &Ngr;,&Ngr;-Diisopropylethylamin einsetzt.
12. Pharmazeutische Zusammensetzung, enthaltend Omeprazol und einen pharmazeutisch unbedenklichen Träger oder ein pharmazeutisch unbedenkliches Verdünnungsmittel, dadurch gekennzeichnet, daß das Omeprazol nach einem der Ansprüche 1-11 hergestellt wird.
13. Nach einem Verfahren gemäß einem der Ansprüche 1-11 hergestelltes Omeprazol.
DE0964859T 1997-11-14 1998-11-03 Neues verfahren Pending DE964859T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704183A SE9704183D0 (sv) 1997-11-14 1997-11-14 New process
PCT/SE1998/001984 WO1999025711A1 (en) 1997-11-14 1998-11-03 New process

Publications (1)

Publication Number Publication Date
DE964859T1 true DE964859T1 (de) 2000-05-04

Family

ID=20408989

Family Applications (1)

Application Number Title Priority Date Filing Date
DE0964859T Pending DE964859T1 (de) 1997-11-14 1998-11-03 Neues verfahren

Country Status (35)

Country Link
US (1) US6303788B1 (de)
EP (1) EP0964859A1 (de)
JP (1) JP2001508466A (de)
KR (1) KR20000070069A (de)
CN (1) CN1145624C (de)
AR (1) AR013740A1 (de)
AU (1) AU750743B2 (de)
BR (1) BR9806871A (de)
CA (1) CA2276753A1 (de)
DE (1) DE964859T1 (de)
DZ (1) DZ2641A1 (de)
EE (1) EE04154B1 (de)
ES (1) ES2138950T1 (de)
GR (1) GR990300046T1 (de)
HR (1) HRP990218A2 (de)
HU (1) HUP0003737A3 (de)
ID (1) ID21999A (de)
IL (1) IL130647A0 (de)
IN (1) IN190801B (de)
IS (1) IS5106A (de)
MA (1) MA26564A1 (de)
MY (1) MY118199A (de)
NO (1) NO318197B1 (de)
NZ (1) NZ336447A (de)
PL (1) PL334701A1 (de)
RU (1) RU2211218C2 (de)
SE (1) SE9704183D0 (de)
SK (1) SK87299A3 (de)
TN (1) TNSN98202A1 (de)
TR (1) TR199901643T1 (de)
TW (1) TW588046B (de)
UA (1) UA68342C2 (de)
WO (1) WO1999025711A1 (de)
YU (1) YU31199A (de)
ZA (1) ZA989999B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
IL142703A (en) 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
JP2004524303A (ja) * 2001-02-02 2004-08-12 テバ ファーマシューティカル インダストリーズ リミティド 置換された２−（２−ピリジルメチル）スルフィニル−１ｈ−ベンゾイミダゾール類の製造方法
SE0203092D0 (en) * 2002-10-18 2002-10-18 Astrazeneca Ab Method for the synthesis of a benzimidazole compound
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
DE602005016705D1 (de) * 2004-10-11 2009-10-29 Ranbaxy Lab Ltd Verfahren zur herstellung substituierter sulfoxide
EP1801110A1 (de) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Argininsalz des Esomeprazols
CN1810803B (zh) * 2006-02-17 2010-11-17 中国科学院上海有机化学研究所 高对映体选择性制备(s)-奥美拉唑的方法
CN101538264A (zh) * 2008-03-19 2009-09-23 中国科学院成都有机化学有限公司 手性亚砜类化合物的制备新方法
CN102603621B (zh) * 2012-02-07 2013-09-04 成都苑东药业有限公司 一种新型手性亚砜化合物和以该化合物制备埃索美拉唑钠的方法
CN106083819A (zh) * 2016-06-08 2016-11-09 扬子江药业集团有限公司 一种奥美拉唑的制备方法
ES2948511A1 (es) * 2021-09-08 2023-09-13 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa Derivados de n-sulfonilureas y su uso terapeutico

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE9002043D0 (sv) 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
NZ244301A (en) 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider

Also Published As

Publication number Publication date
IS5106A (is) 1999-07-02
HUP0003737A3 (en) 2002-01-28
ZA989999B (en) 1999-06-17
TW588046B (en) 2004-05-21
EE9900391A (et) 2000-04-17
AU1058299A (en) 1999-06-07
NO993298D0 (no) 1999-07-02
NO993298L (no) 1999-07-02
KR20000070069A (ko) 2000-11-25
EE04154B1 (et) 2003-10-15
CA2276753A1 (en) 1999-05-27
PL334701A1 (en) 2000-03-13
NZ336447A (en) 2001-02-23
MY118199A (en) 2004-09-30
YU31199A (sh) 2002-06-19
JP2001508466A (ja) 2001-06-26
MA26564A1 (fr) 2004-12-20
UA68342C2 (en) 2004-08-16
NO318197B1 (no) 2005-02-14
EP0964859A1 (de) 1999-12-22
AU750743B2 (en) 2002-07-25
RU2211218C2 (ru) 2003-08-27
CN1145624C (zh) 2004-04-14
DZ2641A1 (fr) 2003-03-15
TR199901643T1 (xx) 2000-01-21
IN190801B (de) 2003-08-23
WO1999025711A1 (en) 1999-05-27
SE9704183D0 (sv) 1997-11-14
CN1243512A (zh) 2000-02-02
IL130647A0 (en) 2000-06-01
SK87299A3 (en) 2000-02-14
GR990300046T1 (en) 2000-07-31
TNSN98202A1 (fr) 2005-03-15
ID21999A (id) 1999-08-19
AR013740A1 (es) 2001-01-10
ES2138950T1 (es) 2000-02-01
HRP990218A2 (en) 2000-08-31
US6303788B1 (en) 2001-10-16
BR9806871A (pt) 2000-04-18
HUP0003737A2 (hu) 2001-10-28

Similar Documents

Publication Publication Date Title
DE964859T1 (de) Neues verfahren
WO1998054171A8 (en) Novel form of s-omeprazole
CA2226184C (en) A process for the optical purification of enantiomerically enriched benzimidazole derivatives
DE69530987T3 (de) Verfahren zur herstellung von substituierten sulfoxiden
RU99117541A (ru) Новый способ
AU2003289948B2 (en) Process for preparing optically pure active compounds
CA2284470A1 (en) New crystalline form of omeprazole
DE69728730D1 (de) Verfahren zur Trennung einer Enantiomermischung
CA2507889C (en) Process for preparing (s)-pantoprazole
EP0931076A1 (de) Methode zur herstellung von omeprazol
JP6325178B2 (ja) エソメプラゾールの光学精製の改良された方法
FR2696743B1 (fr) Nouveaux composés de thiazolidine dione, leur procédé de préparation et les compositions pharmaceutiques les contenant.
WO2005023796A8 (en) New salts of omeprazole and esomeprazole i
AU2005250175A1 (en) Process for the preparation of pyridin-2-ylmethylsulphinyl-1H-benzimidazol compounds
CZ249699A3 (cs) Nový způsob zpracování
TH58464A (th) กรรมวิธีใหม่
MXPA98000160A (en) A process for the optic purification of derivatives of benzimidazol enriquecidos enantiomericame